WallStSmart

Delcath Systems Inc (DCTH)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 40107% more annual revenue ($36.36B vs $90.44M). MDT leads profitability with a 13.2% profit margin vs 0.6%. DCTH appears more attractively valued with a PEG of 1.60. MDT earns a higher WallStSmart Score of 62/100 (C+).

DCTH

Hold

35

out of 100

Grade: F

Growth: 6.7Profit: 3.0Value: 3.7Quality: 7.5
Piotroski: 4/9Altman Z: 1.22

MDT

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for DCTH.

MDTUndervalued (+8.7%)

Margin of Safety

+8.7%

Fair Value

$91.86

Current Price

$83.87

$7.99 discount

UndervaluedFair: $91.86Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DCTH2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0110/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
26.3%8/10

Revenue surging 26.3% year-over-year

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$105.46B9/10

Large-cap with strong market position

Price/BookValuation
2.2x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.1%8/10

Strong operational efficiency at 22.1%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

Areas to Watch

DCTH4 concerns · Avg: 3.3/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

Market CapQuality
$446.71M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.5%3/10

ROE of 0.5% — below average capital efficiency

Profit MarginProfitability
0.6%3/10

0.6% margin — thin

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.624/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : DCTH

The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 26.3% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : DCTH

The primary concerns for DCTH are PEG Ratio, Market Cap, Return on Equity. A P/E of 1294.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Key Dynamics to Monitor

DCTH profiles as a growth stock while MDT is a value play — different risk/reward profiles.

MDT carries more volatility with a beta of 0.58 — expect wider price swings.

DCTH is growing revenue faster at 26.3% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (62/100 vs 35/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Delcath Systems Inc

HEALTHCARE · MEDICAL DEVICES · USA

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?